Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 10/20 | 0.47 |
| ▸ | NQO2 | P16083 | 3/20 | 0.45 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | DRD1 | P21728 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.41 |
| ▸ | HTR6 | P50406 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1455904 | 0.83 | HTR7 (0.60) | HTR7NQO2DRD2DRD1HTR2A | |
| SCHEMBL18025759 | 0.82 | NQO2 (0.43) | HTR7NQO2DRD2DRD1HTR2A | |
| SCHEMBL1455935 | 0.79 | HTR7 (0.43) | HTR7NQO2DRD2DRD1HTR2A | |
| SCHEMBL1456203 | 0.79 | IDO1 (0.64) | HTR7DRD2DRD1HTR2AHTR2C | |
| SCHEMBL24019919 | 0.79 | PGR (0.57) | NQO2TP53POLBMAPTIDO1 | |
| SCHEMBL2988866 | 0.79 | PGR (0.57) | NQO2TP53POLBMAPTIDO1 | |
| SCHEMBL14484522 | 0.77 | NQO2 (0.44) | NQO2TP53POLBMAPTPGR | |
| SCHEMBL1456741 | 0.74 | HTR7 (0.55) | HTR7NQO2DRD2DRD1HTR2A | |
| SCHEMBL319056 | 0.74 | IDO1 (0.66) | HTR7DRD2DRD1HTR2AHTR2C | |
| SCHEMBL4612270 | 0.72 | HTR7 (0.78) | HTR7DRD2DRD1HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7910591-B2 | e.g. 3-[4-(4-Pyridine-2-yl-piperazine-1-yl)-butyl]-1,3-dihydro-2H-indol-2-one; serotonin 5-HT7 and alpha 1 receptors modulator; antxiolytic agent, antidepressant; neurodegenerative diseases; schizophrenia, Alzheimer's disease, stroke, dementias; side effect reduction | EGIS GYOGYSZERGYAR NYRT. (HU) | 2011-03-22 | — | — | US | disclosed |
| US-20090306144-A1 | PYRIDINE DERIVATIVES OF ALKYL OXINDOLES AS 5-HT7 RECEPTOR ACTIVE AGENTS | VOLK BALAZS | 2009-12-10 | — | — | US | disclosed |
| EP-1751106-B1 | PIPERAZINE DERIVATIVES OF ALKYL OXINDOLES | EGIS GYOGYSZERGYAR NYRT (HU) | 2008-10-29 | — | — | EP | disclosed |
| US-20080161323-A1 | Piperazine Derivatives of Alkyl Oxindoles | EGIS GYOGYSZERGYAR RT. (HU) | 2008-07-03 | — | — | US | disclosed |
| US-20070265300-A1 | Pyridine Derivatives of Alkyl Oxindoles as 5-Ht7 Receptor Active Agents | EGIS GYOGYSZERGYAR RT. (HU) | 2007-11-15 | — | — | US | disclosed |
| US-20070219209-A1 | Piperazine Derivatives Of Alkyl Oxindoles | GYÓGYSZERGYÁR RT. (HU) | 2007-09-20 | — | — | US | disclosed |
| EP-1751106-A1 | PIPERAZINE DERIVATIVES OF ALKYL OXINDOLES | EGIS Gyógyszergyár Nyrt (HU) | 2007-02-14 | — | — | EP | disclosed |
| EP-1751134-A1 | PYRIDINE DERIVATIVES OF ALKYL OXINDOLES AS 5-HT7 RECEPTOR ACTIVE AGENTS | EGIS Gyógyszergyár Nyrt (HU) | 2007-02-14 | — | — | EP | disclosed |
| EP-1751105-A1 | PIPERAZINE DERIVATIVES OF ALKYL OXINDOLES | EGIS Gyógyszergyár Nyrt (HU) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005108364-A1 | PIPERAZINE DERIVATIVES OF ALKYL OXINDOLES | EGIS GYÓGYSZERGYÁR NYRT. (HU) | 2005-11-17 | — | — | WO | disclosed |
| WO-2005108363-A1 | PIPERAZINE DERIVATIVES OF ALKYL OXINDOLES | EGIS GYÓGYSZERGYÁR NYRT. (HU) | 2005-11-17 | — | — | WO | disclosed |
| WO-2005108388-A1 | PYRIDINE DERIVATIVES OF ALKYL OXINDOLES AS 5-HT7 RECEPTOR ACTIVE AGENTS | EGIS GYÓGYSZERGYÁR NYRT. (HU) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306144-A1 | PYRIDINE DERIVATIVES OF ALKYL OXINDOLES AS 5-HT7 RECEPTOR ACTIVE AGENTS | HTR7, HTR2C, HTR1A | HTR7 1/4885NQO2 1142/4885DRD2 68/4885 |
| US-20070219209-A1 | Piperazine Derivatives Of Alkyl Oxindoles | TPH2, TPH1, HTR2C | HTR7 30/4885NQO2 1163/4885DRD2 25/4885 |
| US-20070265300-A1 | Pyridine Derivatives of Alkyl Oxindoles as 5-Ht7 Receptor Active Agents | HTR7, HTR2C, HTR1A | HTR7 1/4885NQO2 678/4885DRD2 55/4885 |
| US-20080161323-A1 | Piperazine Derivatives of Alkyl Oxindoles | TPH2, CNR2, HTR5A | HTR7 25/4885NQO2 1507/4885DRD2 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.